| Project/Area Number |
18K16347
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 55020:Digestive surgery-related
|
|---|
| Research Institution | University of Fukui |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2018-04-01 – 2020-03-31
|
| Project Status |
Completed (Fiscal Year 2019)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2019: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2018: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 大腸癌 / 肝転移 / Prokienticin2 / 血管新生因子 / 分子標的薬 / PROK2 / PROK2mRNA / Prokineticin2 |
|---|
| Outline of Final Research Achievements |
Angiogenic factors are associated with prognosis in colorectal cancer. Before, we found that Prokineticin2 (PROK2) mRNA, an angiogenic factor, was expressed in colorectal cancer and was involved in angiogenesis of tumor. Immunostaining of colorectal cancer specimens treated with anti-PROK2 antibody revealed with strong expression. Also,we found the relationship with hematogenous metastases, lymph node metastases, survival rate and recurrence rate. PROK2 was also an independent predictor of recurrence in multivariate analysis. Furthermore, when the PROK2 gene was transfected into a colon cancer cell line and transplanted into the mouse spleen, liver metastasis was increased. From these results, we found that PROK2 has a potential as a recurrence predictor (biomarker) in colorectal cancer and as a therapeutic target.
|
| Academic Significance and Societal Importance of the Research Achievements |
現在、大腸癌における全身化学療法は個別化治療として遺伝子型に応じた治療法が行われている。しかし術後再発予防としての補助化学療法については、再発予測としての明確なバイオマーカーは存在しておらず、進行度に応じて一律に行われている現状があり、また化学療法の副作用が問題視される。今回の研究にてPROK2の新規治療薬としての可能性や、バイオマーカーとしての可能性を見出すことができたことは、予後の改善や症例に応じた個別化治療（不要な化学療法の導入回避や，再発高リスク群や予後不良群のpick up）につなげていくことが可能になると考える。
|
